^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Metastatic Pancreatic Cancer: ASCO Guideline Update

Published date:
08/05/2020
Excerpt:
Recommendations…First-Line Treatment…Gemcitabine plus nab-paclitaxel is recommended…Recommendations…First-Line Treatment…Gemcitabine alone is recommended…The addition of nabpaclitaxel or capecitabine or erlotinib to gemcitabine may be offered in this setting…
DOI:
10.1200/JCO.20.01364 Journal of Clinical Oncology
Evidence Level:
Sensitive: B - Late Trials
Title:

Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region

Published date:
05/25/2020
Excerpt:
Treatment-naive patients with histologically confirmed PC...received nab-P 125 mg/m2 + Gem 1000 mg/m2 or Gem 1000 mg/m2 on days 1, 8, and 15 of six 28-day cycles....The updated OS analysis...revealed a median OS of 41.8 months with nab-P + Gem compared with 37.7 months with Gem alone…
DOI:
10.1200/JCO.2020.38.15_suppl.4515
Trial ID: